The ADA guideline recommends monitoring HbA1c levels at least quarterly after therapy change or if patients do not meet glycemic goals.

For patients with diabetes mellitus type 2 on insulin therapy, the ADA guideline recommends self-monitoring of blood glucose (SMBG) to decrease the risk of hypoglycemia and manage hyperglycemia.

Monitor patients for hypoglycemia with sulfonylureas.

Monitor serum creatinine once a year or every 3 to 4 months in selected patients and adjust the sulfonylurea dose accordingly.

Instruct patients to perform self-glucose monitoring when they develop symptoms of hypoglycemia.